The Duffy Antigen/Receptor for Chemokines (DARC) and Prostate-Cancer Risk among Jamaican Men

详细信息    查看全文

• 作者：Joshua K. Elson (1)
  Jennifer L. Beebe-Dimmer (2)
  Hal Morgenstern (1) (3)
  Mahdavi Chilkuri (4)
  John Blanchard (5)
  Alex B. Lentsch (5)
  
• 关键词：Prostate cancer ; DARC ; African descent ; Epidemiology ; Chemokine receptors ; Erythrocytes
• 刊名：Journal of Immigrant and Minority Health
• 出版年：2011
• 出版时间：February 2011
• 年：2011
• 卷：13
• 期：1
• 页码：36-41
• 全文大小：176KB
• 参考文献：1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-6. CrossRef
  2. Hsing A, Devesa S. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev. 2001;23:3-3.
  3. Bruner D, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer. 2003;107:797-03. CrossRef
  4. Ghafoor A, Jemal A, Cokkinides V, Cardinez C, Murray T, Samuels A, et al. Cancer statistics in African Americans. Cancer J Clin. 2002;52:322-. CrossRef
  5. Glover F Jr, Coffey D, Douglas L, Cadogan M, Russell H, Tulloch T, et al. The epidemiology of prostate cancer in Jamaica. J Urol. 1998;159:1984-. CrossRef
  6. Shen H, Schuster R, Stringer K, Waltz S, Lentsch A. The duffy antigen/receptor for chemokines (DARC) regulates prostate cancer growth. FASEB J. 2006;20:59-4. CrossRef
  7. Hadley T, Peiper S. From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Blood. 1997;89:3077-1.
  8. Szabo M, Soo K, Zlotnik A, Schall T. Chemokine class differences in binding to the Duffy antigen-erythrocyte chemokine receptor. J Biol Chem. 1995;270:25348-1. CrossRef
  9. Addison C, Daniel T, Burdick M, Liu H, Ehlert J, Xue Y, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ chemokine-induced angiogenic activity. J Immunol. 2000;165:52669-7.
  10. Strieter R, Polverini P, Kunkel S, Arenberg D, Burdick M, Kasper J, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogensis. J Biol Chem. 1995;270:27348-7. CrossRef
  11. Ferrer F, Miller L, Andrawis R, Kurtzman S, Albertsen P, Laudone V, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology. 1998;51:161-. CrossRef
  12. Lentsch AB. The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white? FASEB J. 2002;16(9):1093-. CrossRef
  13. Xu L, Ashkenazi A, Chaudhuri A. Duffy antigen/receptor for chemokines (DARC) attenuates angiogenesis by causing senescence in endothelial cells. Angiogenesis. 2007;10(4):307-8. CrossRef
  14. Horton L, Yu Y, Zaja-Milatovic S, Strieter R, Richmond A. Opposing roles of murine Duffy antigen receptor for chemokines and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Cancer Res. 2007;67:9791-. CrossRef
  15. Schaid DJ, McDonnell SK, Zarfas KE, Cunningham JM, Hebbring S, Thibodeau SN. Pooled genome linkage scan of aggressive prostate cancer: results from the international consortium for prostate cancer genetics. Hum Genet. 2006;120:471-5. CrossRef
  16. Olsson M, Hansson C, Avent N, Akesson I, Green C, Daniels G. A clinically applicable method for determining the three major alleles at the Duffy (FY) blood group locus using polymerase chain reaction with allele-specific primers. Transfusion. 1998;38:168-3. CrossRef
  17. Hessner M, Pircon R, Johnson S, Luhm R. Prenatal genotyping of the Duffy blood group system by allele-specific polymerase chain reaction. Prenat Diagn. 1999;19:41-.
  18. Cross A, Peters U, Kirsh V, Andriole G, Reding D, Hayes R, et al. A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res. 2005;65:11779-4. CrossRef
  19. Peiper S, Wang Z, Neote K, Martin A, Showell H, Conklyn M, et al. The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. J Exp Med. 1995;181:1311-. CrossRef
  
• 作者单位：Joshua K. Elson (1)
  Jennifer L. Beebe-Dimmer (2)
  Hal Morgenstern (1) (3)
  Mahdavi Chilkuri (4)
  John Blanchard (5)
  Alex B. Lentsch (5)
  
  1. Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
  2. Karmanos Cancer Institute and Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI, USA
  3. Department of Environmental Health Sciences, School of Public Health and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA
  4. South East Regional Health Authority, Kingston, Jamaica
  5. Department of Surgery, University of Cincinnati, Cincinnati, OH, USA
  

文摘

As an evolutionary response to prevent malaria infection, most Africans do not express the Duffy Antigen/Receptor for Chemokines (DARC) on their red blood cells. Results from experimental studies suggest that DARC expression inhibits prostate-tumor growth. We tested the hypothesis that men of African descent who lack DARC expression are at increased risk of prostate cancer. A case–control study involving 81 age-matched pairs was conducted in Jamaica. Participants were interviewed to collect data, and they donated blood for determination of DARC expression. Logistic regression was used to estimate associations with prostate cancer and aggressive disease. Little or no association was observed between erythrocyte DARC expression and prostate cancer or between DARC expression and aggressive disease. These associations changed little when adjusting for other potential confounders. Our results do not support an effect of erythrocyte DARC expression on the risk or progression of prostate cancer in men of African descent.